Israel has launched an innovative new program to encourage researchers to venture into the field of precision medicine, an emerging medical approach in which treatments are tailored to meet the specific needs of patients and their illnesses.
The Israel Precision Medicine Partnership, launched on Monday at the Israel Museum in Jerusalem, is a collaboration between the Israeli government, including the Planning and Budgeting Committee of the Council for Higher Education and the Digital Israel initiative of the Ministry of Social Equality, and The Klarman Family Foundation, Yad Hanadiv and the Israel Science Foundation.
The initiative will receive $60 million over the next seven years.
Traditionally, drugs are developed and targeted to the “average” patient. But with the cost of genetic sequencing dropping dramatically over the past 15 years, new ways are being developed to match the specific needs of patients. Precision medicine is already making inroads in diagnosing and preventing genetic diseases, and cancer and treatment and diagnosis.
“We know that every person is genetically different from the other, both regarding their molecular properties and how the disease develops in them. This causes them to respond differently to treatments,” said Prof. Benjamin Geiger, chairman of the Academic Board of the Israel Science Foundation, in a phone interview.
“With all the amazing inroads classical medicine has made, in many cases it still fails to give optimal therapeutic solutions to diseases. Some tumors for example develop resistances, and people respond differently to the various treatments offered.”
The idea of the project, Geiger said, is to enable researchers to work closely with physicians and volunteer patients to build a strong molecular profile of patients. They would then analyze the data with powerful computational approaches to try to match the treatment to the individual disease of the person.
“In the future, treatments won’t be just aimed for the ‘average patient’, but therapies will be more precise,” Geiger said. “The researchers partaking in this program will discover novel insights about patients’ molecular profile and the manifestation of the disease, which will enable the selection or development of the most appropriate treatment.”
The vision, he said, is to create “a major turning point” in the practice of medicine, by developing tools that can be made available for practitioners.
Precision medicine is still in its infancy worldwide, with “tremendous activity in the US and leading institutions worldwide,” he added. Israel, however, with its highly diverse population, its strong computational abilities and the culture of cooperation between researchers and physicians, has a strong foundation to make a mark in the field, he added.
(Full disclosure: The Klarman Foundation’s Seth Klarman is the chairman and capital partner of The Times of Israel.)
The Times of Israel covers one of the most complicated, and contentious, parts of the world. Determined to keep readers fully informed and enable them to form and flesh out their own opinions, The Times of Israel has gradually established itself as the leading source of independent and fair-minded journalism on Israel, the region and the Jewish world.
We've achieved this by investing ever-greater resources in our journalism while keeping all of the content on our site free.
Unlike many other news sites, we have not put up a paywall. But we would like to invite readers who can afford to do so, and for whom The Times of Israel has become important, to help support our journalism by joining The Times of Israel Community. Join now and for as little as $6 a month you can both help ensure our ongoing investment in quality journalism, and enjoy special status and benefits as a Times of Israel Community member.